Abstract
Despite preclinical studies suggesting that isradipine may antagonize the abuse liability of cocaine, pretreatment with sustained-release isradipine did not reduce euphoric mood in cocaine-using volunteers. This double-blind, within-subject, crossover laboratory study determined whether maximal dose-loading with isradipine could antagonize effects of cocaine in 12 cocaine-dependent research volunteers administered intravenous cocaine doses (0, 0.325, and 0.65 mg/kg) on different days after 5 days of treatment with isradipine or placebo. Isradipine dose was 30 mg sustained release nightly plus 15 mg immediate release 2 hr before cocaine infusion. Cocaine produced dose-related increases in cocaine's subjective effects and a behavioral measure of reinforcement. Isradipine enhanced, rather than antagonized, subjective effects, indicating that isradipine does not antagonize cocaine's abuse liability in dependent research volunteers.
Original language | English (US) |
---|---|
Pages (from-to) | 319-326 |
Number of pages | 8 |
Journal | Experimental and Clinical Psychopharmacology |
Volume | 13 |
Issue number | 4 |
DOIs | |
State | Published - Nov 2005 |
Keywords
- Calcium channel antagonist
- Cocaine
- Drug abuse
- Isradipine
- Treatment
ASJC Scopus subject areas
- Psychiatry and Mental health
- Pharmacology (medical)
- Pharmacology